Epitalon

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) designed in Russia to reproduce the amino acid composition of Epithalamin, a bovine pineal gland extract, and supplied for laboratory research only. It is not approved by the FDA for any use and is not for human or animal consumption.

Specifications

Origin and research programme

Epitalon comes out of a research line begun by Vladimir Khavinson at what is now the St. Petersburg Institute of Bioregulation and Gerontology. The starting material was Epithalamin, a peptide-containing extract of bovine pineal gland. Epitalon was synthesized as a defined four-residue sequence matching that extract's dominant amino acid composition, on the hypothesis that a chemically identified peptide could stand in for a heterogeneous tissue preparation.

At four residues and under 400 daltons the peptide sits below the size at which receptor pharmacology is the default assumption, and its acidic glutamate and aspartate side chains underlie the DNA-interaction hypothesis pursued by the originating group. Araj et al. (2025), reviewing the field from the Medical University of Warsaw, note that after roughly 25 years of biological work the quantity of physico-chemical and structural investigation of this peptide remains limited.

Mechanistic research

Telomerase and telomere length in vitro

Khavinson, Bondarev and Butyugov (2003) reported in Bulletin of Experimental Biology and Medicine that adding Epitalon to telomerase-negative human fetal fibroblast cultures induced expression of the telomerase catalytic subunit, enzymatic activity of telomerase, and telomere elongation. A companion 2004 report from the same group described cultured human somatic cells dividing past the expected replicative limit. Both are cell-culture reports from the originating institute.

That work went largely unreplicated outside the originating institute for two decades. In 2025, Al-Dulaimi and colleagues at Brunel University London published an independent examination in Biogerontology, treating normal epithelial and fibroblast cells alongside the breast cancer lines 21NT and BT474 and quantifying telomere length, hTERT mRNA, telomerase activity, and alternative lengthening of telomeres (ALT). They reported concentration-dependent telomere extension in normal cells with hTERT and telomerase upregulation, and extension in the cancer lines proceeding instead through ALT activation, with only a minor ALT increase in normal cells. A correction to that paper appeared in the same journal in November 2025. Both papers are cell-culture work; neither establishes that these events occur in tissue within a living organism.

Gene expression and DNA interaction

Khavinson et al. (2020), publishing in Molecules with collaborators in Italy, reported increased synthesis and mRNA expression of the neuronal differentiation markers Nestin, GAP43, β-tubulin III and doublecortin in cultured human gingival mesenchymal stem cells, and used molecular modelling to propose binding of the peptide to histones H1/3 and H1/6 at sites that contact DNA. The originating group's broader hypothesis is that short acidic peptides reach the nucleus and influence transcription through such interactions. That hypothesis has generated binding and modelling work, but the modelling component is computational rather than experimental, and the question is not settled.

Animal research

The in vivo record is dominated by rodent longevity and carcinogenesis studies from the Petrov Institute of Oncology and collaborators, and it is more mixed than secondary summaries convey. Anisimov et al. (2003) followed female outbred Swiss-derived SHR mice, 54 per group, from three months of age to natural death. They reported that Epitalon did not change food consumption, body weight, or mean life span, and did not change total spontaneous tumour incidence. They did report slowed age-related decline of estrous function, fewer bone marrow chromosome aberrations, increases in maximum life span and in the life span of the last 10 percent of survivors, and a reduction in leukemia specifically. The authors characterised their own result as geroprotector activity in this mouse strain, together with tolerability of long-term administration in mice. The finding set is mixed and species-bound, and no equivalent human evidence exists.

Vinogradova et al. (2007) examined life span and development of spontaneous tumours in female rats maintained under different illumination regimes.

Study models at a glance

Human data

No controlled trial indexed in PubMed has measured telomere length in humans before and after administration of Epitalon under blinded conditions. Claims circulating about human outcomes are not supported by trial evidence of that kind. The published human-relevant work is in vitro, and the in vivo record is rodent; both should be read as such. Where secondary sources describe human results, the underlying reports are largely unblinded, uncontrolled, or concern the Epithalamin extract rather than the defined tetrapeptide.

Regulatory status

Epitalon holds no FDA approval, no New Drug Application, and no legal status as a dietary ingredient in the United States. No USP or Ph. Eur. monograph exists, so there is no pharmacopoeial identity or purity standard to test against. Vanhee et al. (2015), at the Belgian Scientific Institute of Public Health, reported an analytical identification of Epitalon in two preparations seized as illegal pharmaceuticals; their title records the therapeutic claims those sellers had attached to the material, and the analysis was undertaken precisely because such claims were unsupported. Material bearing this name has circulated with no analytical oversight. Terms of sale are set out in the research use policy.

Handling, storage, and identity verification

Epitalon is supplied as a lyophilized powder. Sealed vials should be kept desiccated at −20 °C or colder, protected from light, and allowed to reach room temperature before opening to avoid condensation. Freeze-thaw cycling of solutions is the degradation route that matters most in stability work. Related handling references: peptide storage, reconstitution, and the peptide calculator for concentration arithmetic.

Four-residue peptides are a genuine analytical problem, and this is where supplier paperwork deserves scrutiny. At 390 g/mol Epitalon is poorly retained on standard reversed-phase columns, and because the sequence contains no aromatic residue it produces no useful absorbance at 280 nm. Detection has to fall back on the amide backbone near 210–215 nm, where mobile-phase contaminants and solvent-front artefacts interfere far more readily. A purity figure from a method not adapted to that can be meaningless. Useful lab testing documents the chromatographic conditions, an actual trace, and a mass spectrum with an observed ion consistent with 390.35 g/mol.

Frequently asked questions

How should lyophilized Epitalon be stored?

Sealed, desiccated, and protected from light at −20 °C or colder. Brief ambient excursions in transit are expected; extended room-temperature storage is not.

Why is purity analysis harder for a peptide this small?

Short, highly polar peptides are weakly retained on reversed-phase columns, and a sequence with no aromatic residue gives no useful absorbance at 280 nm. That leaves low-wavelength detection near 210–215 nm, where interference is greater. A certificate of analysis should document the method and show the trace, not merely report a number.

What is the difference between Epitalon and Epithalamin?

Epithalamin is a bovine pineal gland extract, a heterogeneous biological preparation. Epitalon is a single synthetic tetrapeptide built to match that extract's dominant amino acid composition. The two are not interchangeable, and literature on one does not transfer to the other.

Is Epitalon approved by the FDA?

No. It is not approved for any indication in the United States, is not a recognized dietary ingredient, and is offered for laboratory research only. It is not for human or animal consumption.

References

1. Khavinson VKh, Bondarev IE, Butyugov AA (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine.
2. Anisimov VN, Khavinson VKh, Popovich IG, et al. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology.
3. Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD (2004). Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine.
4. Vinogradova IA, Bukalev AV, Zabezhinski MA, et al. (2007). Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. Bulletin of Experimental Biology and Medicine.
5. Vanhee C, Moens G, Van Hoeck E, Deconinck E, De Beer JO (2015). Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and Retinitis Pigmentosa in two illegal pharmaceutical preparations. Drug Testing and Analysis.
6. Khavinson V, Diomede F, Mironova E, et al. (2020). AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules.
7. Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł (2025). Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences.
8. Al-Dulaimi S, Thomas R, Matta S, Roberts T (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology.
9. Al-Dulaimi S, Thomas R, Matta S, Roberts T (2025). Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology.